Antivirals for influenza in healthy adults: systematic review. (Q30352729)

20 June 2017

1 reference

0 references

1 reference

title

Antivirals for influenza in healthy adults: systematic review. (English)

1 reference

20 June 2017

1 reference

T Jefferson

1

1 reference

20 June 2017

V Demicheli

2

1 reference

20 June 2017

D Rivetti

3

1 reference

20 June 2017

M Jones

4

1 reference

20 June 2017

C Di Pietrantonj

5

1 reference

20 June 2017

A Rivetti

6

1 reference

20 June 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

20 June 2017

1 reference

20 June 2017

367

1 reference

20 June 2017

9507

1 reference

20 June 2017

303-313

1 reference

Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.

20 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Amantadine and rimantadine for preventing and treating influenza A in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Neuraminidase inhibitors for preventing and treating influenza in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Amantadine hydrochloride as a prophylactic in respiratory infections. A double-blind investigation of its clinical use and serology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Therapeutic effect of 1-adamantanamine hydrochloride in naturally occurring influenza A 2 -Hong Kong infection. A controlled double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Therapeutic effects of aerosolized amantadine in naturally acquired infection due to influenza A virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Prevention of influenza A/USSR/77 (H1N1): an evaluation of the side effects and efficacy of amantadine in recruits at Fort Sam Houston

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Prevention of Russian Influenza by Amantadine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Protection of Man from Natural Infection with Influenza A2 Hong Kong Virus by Amantadine: A Controlled Field Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Evaluation of amantadine in the prophylaxis of influenza A (H1N1) virus infection: a controlled field trial among young adults and high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Comparison of amantadine and rimantadine for prevention of type A (Russian) influenza

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Treatment of influenza. The therapeutic efficacy of rimantadine HC1 in a naturally occurring influenza A2 outbreak

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Trial of amantadine in epidemic influenza

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir for prophylaxis against influenza--placebo-controlled double-blind multicenter phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza--placebo-controlled double-blind multicenter phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Avian influenza A (H5N1) infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Human illness from avian influenza H7N3, British Columbia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

Oseltamivir resistance during treatment of influenza A (H5N1) infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967970-1

7 January 2021

10.1016/S0140-6736(06)67970-1

Identifiers

DOI

1 reference

20 June 2017

1 reference